PHRR210930-003966
Clofazimine and moxifloxacin PK, safety and AccepTAbiLitY for paediatric TB treatment (CATALYST)
The pharmacokinetics, safety and acceptability of new child-friendly formulations of clofazimine and moxifloxacin in children routinely treated for rifampicin-resistant tuberculosis
STELLENBOSCH UNIVERSITTY·Phase 1/2·Philippine Health Research RegistryOngoing
Study focus
- Disease/Condition
- Tuberculosis
- Study type
- Interventional
Sponsor & location
- Primary sponsor
- STELLENBOSCH UNIVERSITTY
- Funder
- UNITAID
- Location
- India Philippines South Africa
Timeline & enrollment
- Phase
- Phase 1/2
- Start date
- Oct 28, 2020
- End date
- N/A
ICD-10 classifications
TuberculosisLatent tuberculosisTuberculosis of other organsCongenital tuberculosisSequelae of tuberculosis
Data source
- Registry
- Philippine Health Research Registry
- Trial ID
- PHRR210930-003966
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for PHRR210930-003966 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by STELLENBOSCH UNIVERSITTY and is currently Ongoing. The study focuses on Tuberculosis.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Philippine Health Research Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.